1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Adrenal Corticosteroid Inhibitors Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing need for adrenal corticosteroid inhibitors to treat endocrine diseases
5.1.1.2. Rising government approvals for adrenal corticosteroid inhibitors-based drugs
5.1.2. Restraints
5.1.2.1. Limited awareness and high cost associated with adrenal corticosteroid inhibitors
5.1.3. Opportunities
5.1.3.1. Significant investments in research and development of adrenal corticosteroid inhibitors
5.1.3.2. Growing presence of refined medical facilities and advances in pharmaceutical sector
5.1.4. Challenges
5.1.4.1. Concerns regarding side impacts of adrenal corticosteroid inhibitors-based drugs
5.2. Market Segmentation Analysis
5.2.1. Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases
5.2.2. Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing’s syndrome
5.2.3. Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors
5.2.4. End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Adrenal Corticosteroid Inhibitors Market, by Drug
6.1. Introduction
6.2. Aminoglutethimide
6.3. Levoketoconazole
6.4. Metyrapone
6.5. Osilodrostat
7. Adrenal Corticosteroid Inhibitors Market, by Treatment Type
7.1. Introduction
7.2. Breast Cancer
7.3. Cushing’s Syndrome
7.4. Prostate Cancer
8. Adrenal Corticosteroid Inhibitors Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Adrenal Corticosteroid Inhibitors Market, by End-user
9.1. Introduction
9.2. Hospitals
9.3. Speciality Centres
10. Americas Adrenal Corticosteroid Inhibitors Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Adrenal Corticosteroid Inhibitors Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Adrenal Corticosteroid Inhibitors Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Agreement, Collaboration, & Partnership
13.3.1.1. Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
13.3.2. Award, Recognition, & Expansion
13.3.2.1. Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
13.3.2.2. U.S. FDA Approves AKEEGA (Niraparib and Abiraterone Acetate), the Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AbbVie Inc.
14.1.2. Adooq Bioscience LLC
14.1.3. Cayman Chemical Company
14.1.4. Crinetics Pharmaceuticals, Inc.
14.1.5. Eli Lilly and Company
14.1.6. Enzo Life Sciences, Inc.
14.1.7. Hefei Home Sunshine Pharmaceutical Technology Co., Ltd.
14.1.8. HRA Pharma Rare Diseases SAS by Perrigo Company plc
14.1.9. MedChemExpress
14.1.10. Merck KGaA
14.1.11. Novartis AG
14.1.12. Orphagen Pharmaceuticals
14.1.13. Pfizer Inc.
14.1.14. Sparrow Pharmaceuticals Inc.
14.1.15. Steris Healthcare PVT Ltd
14.1.16. Tocris Bioscience by Bio-Techne Corporation
14.1.17. Xeris Biopharma Holdings, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
